Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
Authors:
- S.H. KennedySKS.H. Kennedy
- R. EmsleyRER. Emsley
- 1 February 2006
- journal article
- research article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 16 (2) , 93-100
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein β3 subunit as predictors of response to fluoxetine and nortriptylineInternational Journal of Neuropsychopharmacology, 2003
- AgomelatineDrugs of the Future, 2003
- Mirtazapine Versus Venlafaxine in Hospitalized Severely Depressed Patients With Melancholic FeaturesJournal of Clinical Psychopharmacology, 2001
- Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamineInternational Clinical Psychopharmacology, 2001
- Antidepressants in clinical practice: limitations of assessment methods and drug responseHuman Psychopharmacology: Clinical and Experimental, 2001
- Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerabilityJournal of Affective Disorders, 2000
- Conceptualization and Rationale for Consensus Definitions of Terms in Major Depressive DisorderArchives of General Psychiatry, 1991
- Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter studyJournal of Affective Disorders, 1990
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960